A team of researchers from five Swedish universities have made a remarkable breakthrough in the treatment of cancer, with an equally innovative source of funding.
“We are first to show this new way of targeting cancer and this is likely going to be the major path for drug development in the future,” said Thomas Helleday, holder of the Söderberg Professorship at Karolinska Institutet, who heads the study.
Until now, most modern anti-cancer drugs have been tailored to target the genetic makeup of the cancer – a so-called personalized treatment. Sometimes this can have a long-lasting effect, but more often than not the cancers mutate to become resistant. What the team has managed to do is to target an enzyme that is required for all cancer cells for survival, but that normal cells do not need.
Helleday explained that the treatment – which comes in the form of a pill – can kill any cancer and does not have any severe side effects.
“Some say our finding sounds too good to be true, and I understand their gut feeling after seeing so many promising cancer treatments fail,” he said. “My research group has made paradigm shifts before and to those skeptics I say: just sit back and enjoy the revolution!”
What’s also revolutionary is the way the research is financed, through “open innovation” and “crowd sourcing”.
“I started a public foundation that owns all intellectual property and the idea is that we manufacture large amounts of the drug and provide it for free to the worldwide academic community, so they can design their own clinical trials and run them”, Helleday said.
“Also, as there is a public foundation behind the drug, it will not be used to enrich a few individuals, but be used for further work on new medicines.”
A lot of work remains to be done before it is time for clinical trials, which are still a year or two away, Helleday said.
Being based in Stockholm brings many advantages, including a number of highly trained drug developers looking for new challenges, he said.
“A major point is that Swedish Universities do not claim or take control on intellectual property, allowing us to donate it to a public foundation,” Helleday said.
“Another advantage is the collaborative nature of Swedes. We collaborated with five different universities to progress the project, which would have been difficult elsewhere.”
Their concept is presented in two articles in science journal Nature, with the aim of spreading the word to as many as possible in the research community.
“It has generated interest from academics across the world, to try the new concept on the cancer indication they have specialized in,” Helleday said.
The team has also sent out the compound to hundreds of scientists across the globe in an effort to increase the speed of innovation and to reach the goal of curing cancer more quickly. By freely sending out compounds, they have increased competition.
“Hundreds of scientists are advancing more quickly than one and we increase the chances of overall success,” Helleday said.
The Latest on: Cancer breakthrough
via Google News
The Latest on: Cancer breakthrough
- How a simple nasal swab could help a Peninsula company redefine lung cancer riskon October 11, 2021 at 4:39 pm
A swab of the nose could help doctors triage lung cancer patients to determine who need a closer look and who can skip time-consuming, stress-inducing, expensive and invasive procedures. Veracyte Inc.
- Medical Minute: Breakthroughs In Breast Cancer Careon October 11, 2021 at 2:42 pm
Breast cancer impacts 1 in 8 American women. Doctors are constantly researching new ways to diagnose and treat the disease. In today's medical minute, we're looking into the recent breakthroughs in ...
- Breakthroughs in Metastatic Breast Cancer From ESMO 2021on October 8, 2021 at 6:57 am
Dr Javier Cortes presents practice-changing data on metastatic breast cancer from ESMO 2021, including trastuzumab deruxtecan in HER2+ disease, pembrolizumab in TNBC, and ribociclib in HR+/HER2- ...
- Cancer breakthrough: Exercise may stop disease in its trackson October 5, 2021 at 6:56 am
New research from Edith Cowan University shows bed and rest might not be the best treatment for people suffering from cancer – in fact, the opposite may be true. ECU researchers have discovered the ...
- FDA Grants Trastuzumab Deruxtecan Breakthrough Therapy Designation for Treatment of Unresectable or Metastatic HER2-Positive Breast Canceron October 5, 2021 at 6:09 am
The designation was based on data from the DESTINY-Breast03 phase 3 trial, and this is now the second BTD for trastuzumab deruxtecan in breast cancer, bringing its total number of BTDs to 4, according ...
- Possible Breakthroughs in Advanced Bladder and Cervical Cancer: Day 2 of the European Society for Medical Oncology’s 2021 Congresson October 4, 2021 at 5:00 pm
Strong study results in two phase 3 clinical trials may soon change go-to care, plus a promising treatment for bladder cancer inches closer to a new indication.
- FDA Grants Breakthrough Therapy Designation to Trastuzumab Deruxtecan for Select HER2+ Metastatic Breast Canceron October 4, 2021 at 8:56 am
The FDA has granted a breakthrough therapy designation to trastuzumab deruxtecan-nxki for use in adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received ...
- Debiopharm Encourages Breakthrough Cancer Research in Japan Through its Competitive JCA Mauvernay Awardon October 4, 2021 at 12:08 am
Debiopharm ( a Swiss-based global biopharmaceutical company, today announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories ...
- AstraZeneca Says FDA Granted Breakthrough-Therapy Designation for Cancer Treatment Enhertuon October 3, 2021 at 11:41 pm
By Anthony O. Goriainoff AstraZeneca PLC said Monday that the U.S. Food and Drug Administration granted its cancer treatment Enhertu a ...
- Breast Cancer Awareness | Seeing breakthroughs: Cancer medicines zeroing in on cell targetson September 30, 2021 at 9:00 pm
JOHNSTOWN, Pa. – Just a few years ago, if a new drug showed promise in one type of cancer, researchers would start randomly trying it with other cancers.
via Bing News